The incidence of chronic myeloid leukemia (CML) ranges between 10 and 15
cases/106/year (age adjusted) without any major geographic or ethnic differences [1]. The …

The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …

New insights have emerged from maturing long-term academic and commercial clinical
trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of …

Patients with splenomegaly and abnormally high leukocyte counts were first recognized in
France, Germany, and Scotland in the 1840s. The only well-documented therapy in the 19th …

Achieving successful outcomes in chronic phase‐chronic myeloid leukemia (CP‐CML)
requires careful monitoring of cytogenetic/molecular responses (CyR/MR). SIMPLICITY …

The median age of chronic myeloid leukemia (CML) patients is∼ 60 years, and age is still
considered an important prognostic factor, included in Sokal and EURO risk scores …

Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated
chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) …

The BCR:: ABL1 tyrosine kinase inhibitors (TKIs) have improved the outcomes of patients
with chronic myeloid leukemia (CML). After failing second‐generation TKI (2G‐TKI), the …

Background BCR-ABL1 tyrosine kinase inhibitors (TKIs) have significantly improved the
survival outcomes for patients with chronic myeloid leukemia (CML). In addition to imatinib, 3 …

Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia
(CML). With TKI therapy, the percentage of patients who progress to accelerated phase (AP) …